NEWPORT BEACH, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Mammogen, a female-led predictive health company developing RNA-powered molecular diagnostics for women's health, today announced an up to $30 million institutional Series A equity financing led by a major U.S. public retirement system. The financing is structured to support Mammogen's next phase of growth, including its pivotal prospective clinical program and commercialization expansion.

The Series A positions Mammogen among the most significantly capitalized emerging companies in women's health diagnostics at a moment when demand for more predictive, molecular approaches to screening is accelerating, driven by regulatory tailwinds around breast density notification, increasing consumer engagement in proactive health, and a rapidly evolving digital health distribution landscape.

Founded within the broader IV BioHoldings (IVBH) ecosystem, an innovation platform focused on advancing scalable early detection technologies across multiple disease areas, Mammogen was created to pioneer a more predictive and molecularly informed approach to women's health diagnostics. The company's lead product candidate, genTRU-breast™, is a blood-based molecular assay designed to support earlier breast cancer detection, particularly for women with dense breast tissue where traditional screening approaches alone can face meaningful limitations.

"Mammogen was founded on the conviction that women deserve access to diagnostics that detect ...